Helix Biopharma Corp. Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Helix Biopharma Corp. in the next few years
Pros
?
M***** P*******
?
B****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Helix Biopharma Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Helix Biopharma Corp. | - | - | - | - | - | - | - |
| Resverlogix Corp | -2.110% | 6.400% | 14.655% | 121.667% | 146.296% | -42.672% | -88.125% |
| Enwave Corporation | -5.410% | 7.843% | -1.786% | 81.818% | 59.420% | -27.632% | -70.861% |
| Aurinia Pharmaceuticals Inc. | -1.040% | -3.268% | 6.566% | 62.289% | 54.225% | 209.442% | 7.933% |
News
BioCardia Narrows Loss in Fiscal Q2
BioCardia (NASDAQ:BCDA), a clinical-stage cell therapy company focused on treatments for heart disease, released its financial results for the second quarter of 2025 on August 11, 2025. The company
Helix Energy Q2 Revenue Falls 17%
Helix Energy Solutions Group (NYSE:HLX), a diversified offshore energy services provider, reported weaker-than-expected Q2 2025 results, released on July 23, 2025. The headline was a disappointing